AstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +22.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
AstraZeneca PLC (AZN) Current ratio
AstraZeneca PLC's current ratio at the end of the quarter to 30 September 2026 was 1.0×, up 0.1× from fiscal 2025 (0.9×). Over the past ten years it has ranged from 0.8× (fiscal 2017) to 1.2× (fiscal 2021); the current reading is higher than 64% of that period. That is below the Drug Manufacturers General industry median of 1.4× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 0.9× | 1.22% |
| FY2024 | 0.9× | 12.98% |
| FY2023 | 0.8× | (4.54%) |
| FY2022 | 0.9× | (26.02%) |
| FY2021 | 1.2× | 20.69% |
| FY2020 | 1.0× | 12.04% |
| FY2019 | 0.9× | (10.24%) |
| FY2018 | 1.0× | 19.22% |
| FY2017 | 0.8× | (7.66%) |
| FY2016 | 0.9× | (19.25%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 1.0× | 13.48% |
| Jun 2026 | 0.9× | (2.52%) |
| Mar 2026 | 0.9× | (3.08%) |
| Dec 2025 | 0.9× | 6.70% |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| BMY Bristol Myers Squibb Company compare | 1.6× |
| AMGN Amgen Inc. compare | 1.5× |
| PFE Pfizer Inc. compare | 1.4× |
| GILD Gilead Sciences, Inc. compare | 1.4× |
| MRK Merck & Co., Inc. compare | 1.3× |
| AZN AstraZeneca PLC | 1.0× |
| NVS Novartis AG compare | 0.9× |
| NVO Novo Nordisk A/S compare | 0.9× |
| ABBV AbbVie Inc. compare | 0.9× |
| Drug Manufacturers General industry median | 1.4× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on AZN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement